News and Press
Interview with portfolio company IM Therapeutics on HLA targeted immune therapy treatments
March 30, 2021
JDRF T1D Fund Managing Director Steven St. Peter sat down with Nandan Padukone and Peter Gottlieb of IM Therapeutics to discuss the company’s progress in creating HLA targeted immune therapy treatments for T1D and other autoimmune diseases.